Randomised trials comparing chemotherapy in advanced NSCLC with best supportive care (1988–2001)
| Reference | No of patients | Regime | Median (range) age | Quality of life | Survival | p value (survival) |
|---|---|---|---|---|---|---|
| P = cisplatin; Vd = vindesine; C = cyclophosphamide; A = doxorubicin; V = vinblastine; I = ifosfamide; E = epirubicin; Et = etoposide; M = mitomycin; T = paclitaxel; D = docetaxel; VNR = vinorelbine; G = gemcitabine; Cb = carboplatin; + = statistically significant; − = not significant. | ||||||
| *Second line treatment. | ||||||
| 93 | 351 | MIP | 62 (41–75) | + | + | 0.03 |
| 95 | 207 | D | 59 (36–75) | + | + | 0.026 |
| 96 | 191 | VNR | 74 (70–85) | + | + | 0.02 |
| 151 | 251 | PVd | NR | + | 0.01 | |
| CAP | 0.05 | |||||
| 152 | 63 | PV | − | − | 0.09 | |
| 153 | 48 | CbEt | + | + | NR | |
| 154 | 287 | IEP | 58 (36–73) | + | + | 0.0003 |
| MVP | 58 (28–76) | |||||
| 155 | 157 | T | 65 (37–78) | + | + | 0.037 |
| 156* | 104 | D | 61 (37–76) | + | + | 0.047 |
| 157 | 300 | G | 65 (37–82) | + | − | 0.84 |